Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Shares in biotech company Recursion Pharmaceuticals ( RXRX 12.07%) surged by more than 12% by 11 a.m. ET today. The move is ...

Symptoms of a vitamin C deficiency include weakness, bruising, and dry skin. Learn more about the warning signs and how to ...

EMJ spoke with Lukas Rasulic to explore the latest advances in peripheral nerve repair, the integration of functional ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease (COPD). However, patients would benefit from better identification of ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...